ELISA/assay

Rat Insulin-like growth factor binding protein 3, IGFBP-3 ELISA Kit

MBS704119

48-Strip-Wells

465 USD

ELISA Kit

Rat Insulin-like growth factor binding protein 3, IGFBP-3 ELISA Kit

insulin-like growth factor binding protein 3

Rat Insulin-like growth factor binding protein 3; IGFBP-3 ELISA kit; tcag7.703; BP-53; IBP3; IGF-binding protein 3; acid stable subunit of the 140 K IGF complex; binding protein 29; binding protein 53; growth hormone-dependent binding protein; insulin-like growth factor binding protein 3

insulin-like growth factor-binding protein 3; Insulin-like growth factor-binding protein 3; insulin-like growth factor-binding protein 3; IBP-3; IGFBP-3; IGF-binding protein 3; insulin-like growth factor-binding protein (IGF-BP3); insulin-like growth factor binding protein 3

IGFBP3

Igfbp3; Igfbp3; IGF-BP3; Igfbp-3; IBP-3; IGF-binding protein 3; IGFBP-3

IBP3_RAT

Rat

292

This assay has high sensitivity and excellent specificity for detection of Rat IGFBP3. No significant cross-reactivity or interference between Rat IGFBP3 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Detection Range: 0.94 ng/ml-60 ng/ml. Sensitivity: 0.23 ng/ml

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV% is less than 8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV% is less than 10%. Three samples of known concentration were tested in twenty assays to assess. Detection Wavelength: 450 nm. Sample Volume: 50-100ul

Introduction: Insulin-like growth factor (IGF) binding proteins (IGFBPs) play a pivotal role in the regulation of IGF activity and availability in the circulation and extracellular environment. All IGFBP family members are cysteine-rich proteins with high binding affinity for IGF-I and IGF-II. IGFBPs can inhibit IGF actions, enhance IGF actions, or function independently as cell regulatory factors (for reviews, see references. IGFBPs act as transporters of IGF, prolonging the life of IGF within the body. IGFBP-3, the major IGF binding protein in plasma, exists in a ternary complex with IGF-I or IGF-II and an acid-labile subunit (ALS). The full-length cDNA for IGFBP-3 encodes a precursor protein of 291 amino acids (aa) with a putative 27 aa signal peptide. Cleavage of the signal peptide generates the 264 aa mature protein. IGFBP-3 contains three potential N-linked and two potential O-linked glycosylation sites. Post-translational modifications such as glycosylation, phosphorylation and/or proteolysis may significantly influence the regulation of IGFBP-3 physiology. Studies have also suggested that the three-dimensional structure of the IGFBP-3 protein itself plays an important role in IGF binding. Substitutions for hydrophobic amino acids within the N-terminal domain of IGFBP-3 markedly reduce IGF-I binding and attenuate inhibition of IGF-I-stimulated cell migration and DNA synthesis. Residues 228 - 232 of IGFBP-3 are essential for cell association and are required for normal ALS binding affinity. IGFBP-3 is expressed in multiple tissues. Circulating IGFBP-3 originates mainly from hepatic non-parenchymal cells. Expression levels are higher during extrauterine life and peak during puberty. Circulating levels of IGFBPs are regulated by both hormonal and metabolic factors. For example, prolonged periods of severe malnutrition can result in depressed levels of IGFBP-3. Cytokines have also been shown to regulate IGFBP-3 expression. EGF and TGF- 1, growth factors known to be active in skin, can significantly reduce IGFBP-3 expression by keratinocytes. TGF- 1 can also regulate IGFBP-3 expression by glomerular endothelial cells, fetal chondrocytes, intestinal muscle cells, and fibroblasts. Principle of the Assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to IGFBP-3. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific for IGFBP-3 and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB (3,3',5,5' tetramethyl-benzidine) substrate solution is added to each well. Only those wells that contain IGFBP-3, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm +/- 2 nm. The concentration of IGFBP-3 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

298231182

NP_036720.2

NM_012588.2

P15473

31,680 Da

Myometrial Relaxation And Contraction Pathways (198465); Transcriptional Misregulation In Cancer Pathway (523027); Transcriptional Misregulation In Cancer Pathway (522987); P53 Pathway (219776); P53 Signal Pathway (198463); P53 Signaling Pathway (83447); P53 Signaling Pathway (465)

an insulin growth factor (Igf) binding protein; involved in modulating IGF-I action [RGD, Feb 2006]

Function: IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.

48-Strip-Wells

465 USD

96-Strip-Wells

655

5x96-Strip-Wells

2455

10x96-Strip-Wells

4595